SCHEMBL4658238

SCHEMBL4658238

Cc1ccccc1-c1c(NC(=O)O)ccc2nc(N3CCOCC3)ccc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 10/20 0.47
ALDH1A1 P00352 8/20 0.47
GAA P10253 3/20 0.47
HPGD P15428 3/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HIF1A Q16665 3/20 0.47
CNR2 P34972 1/20 0.46
GBA1 P04062 4/20 0.46
CYP1A2 P05177 2/20 0.46
TSHR P16473 2/20 0.46
MAPK1 P28482 2/20 0.46
USP2 O75604 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C9 P11712 1/20 0.46
ALOX15 P16050 1/20 0.46
CYP2C19 P33261 1/20 0.46
CASP7 P55210 1/20 0.46
CLK4 Q9HAZ1 1/20 0.46
LMNA P02545 2/20 0.45
HTT P42858 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4761189 0.84 TACR1 (0.51) KDM4EALDH1A1GAAHIF1ARAB9A
SCHEMBL14349115 0.83 MCHR1 (0.46) KDM4EGAAHPGDTSHRNPC1
SCHEMBL4658327 0.81 ALDH1A1 (0.52) KDM4EALDH1A1GAAHPGDSMN1; SMN2
SCHEMBL4658361 0.79 KDM4E (0.49) KDM4EALDH1A1GAAHPGDSMN1; SMN2
SCHEMBL5654093 0.77 GBA1 (0.61) KDM4EALDH1A1GAAHPGDSMN1; SMN2
SCHEMBL4659141 0.77 MCHR1 (0.42) KDM4EALDH1A1GAAHPGDSMN1; SMN2
SCHEMBL4763880 0.76 MET (0.42) KDM4EALDH1A1GAAHPGDSMN1; SMN2
SCHEMBL20642000 0.73 KDM4E (0.55) KDM4EALDH1A1GAAHIF1ACYP1A2
SCHEMBL4660444 0.73 TACR1 (0.67) CYP3A4
SCHEMBL5652612 0.73 ALDH1A1 (0.46) KDM4EALDH1A1HPGDSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1819342-A4 QUINOLINE TACHYKININ RECEPTOR ANTAGONISTS MERCK & CO INC (US) 2008-12-17 EP disclosed
US-20070293492-A1 Quinoline Tachykinin Receptor Antagonists MERCK SHARP & DOHME CORP. 2007-12-20 US disclosed
EP-1819342-A1 QUINOLINE TACHYKININ RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 2007-08-22 EP disclosed
WO-2006060390-A1 QUINOLINE TACHYKININ RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2006-06-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070293492-A1 Quinoline Tachykinin Receptor Antagonists TACR1, TACR2, NPSR1 KDM4E 2973/4885ALDH1A1 874/4885GAA 1131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.